ADAL

Across TCGA pan-cancer cohorts, ADAL mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ADAL data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ADAL mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ADAL expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

HNSC, CCRCC, and GBM are the cancer types where ADAL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.933	1.000	.002	20	view →
CCRCC	DFS	Tertile	All	1.000	0.573	.012	9	view →
GBM	OS	Median	All	0.957	0.762	.008	6	view →
PDAC	DFS	Quartile	II,III,IV	0.481	0.294	.037	2	view →
LUAD	OS	Quartile	II,III,IV	0.303	0.824	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ADAL–HNSC (OS)

Open the HNSC breakdown →